{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:03:25Z","timestamp":1790129005921,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["PD190057"],"award-info":[{"award-number":["PD190057"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-023919"],"award-info":[{"award-number":["MJFF-023919"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009797","name":"Barrow Neurological Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017770","name":"Kemper and Ethel Marley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e01040","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:06:53Z","timestamp":1787814413000},"page":"e01040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk"],"prefix":"10.1016","volume":"23","author":[{"given":"Giovanni R.","family":"Malaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Killion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Anmisha","family":"Doddamreddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo J.","family":"Laurido-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A.","family":"Racette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2026.e01040_bib1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson's disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e01040_bib2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/WNL.0b013e3181a26b30","article-title":"Brain iron homeostasis and neurodegenerative disease","volume":"72","author":"Benarroch","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/mds.20362","article-title":"Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease","volume":"20","author":"Ahlskog","year":"2005","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molbrainres.2004.09.014","article-title":"Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?","volume":"134","author":"Maguire-Zeiss","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1602\/neurorx.2.3.484","article-title":"Toxin-induced models of Parkinson's disease","volume":"2","author":"Bove","year":"2005","journal-title":"NeuroRx"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mds.26477","article-title":"Autophagy and Alpha-Synuclein: relevance to Parkinson's Disease and related synucleopathies","volume":"31","author":"Xilouri","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurot.2026.e01040_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fneur.2013.00033","article-title":"Molecular events underlying Parkinson's disease - an interwoven tapestry","volume":"4","author":"Lim","year":"2013","journal-title":"Front Neurol"},{"issue":"70","key":"10.1016\/j.neurot.2026.e01040_bib8","first-page":"9","article-title":"The discovery of dopamine deficiency in the parkinsonian brain","author":"Hornykiewicz","year":"2006","journal-title":"J Neural Transm Suppl"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01040_bib9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/mds.20399","article-title":"Dopaminergic innervation of the human striatum in Parkinson\u2019s disease","volume":"20","author":"Porritt","year":"2005","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01040_bib10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mds.21033","article-title":"Oscillations in the basal ganglia under normal conditions and in movement disorders","volume":"21","author":"Gatev","year":"2006","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01040_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"Parkinson Study Group QEI. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"issue":"20","key":"10.1016\/j.neurot.2026.e01040_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","article-title":"Effect of deprenyl on the progression of disability in early Parkinson's disease","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","author":"Schwarzschild","year":"2014","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib14","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-linded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01040_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early parkinson disease: a randomized trial","volume":"172","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01040_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","article-title":"Evaluation of simvastatin as a disease-modifying treatment for patients with parkinson disease: a randomized clinical trial","volume":"79","author":"Stevens","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01040_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Writing Group for the NETiPDI. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial","volume":"313","author":"Kieburtz","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-lind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01040_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson\u2019s disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-lind, randomized, controlled trial","volume":"78","author":"Warren Olanow","year":"2015","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01040_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-lind, randomised trial","volume":"14","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e01040_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2017.06.137","article-title":"Emerging roles of protein kinases in microglia-mediated neuroinflammation","volume":"146","author":"Lee","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01040_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/frdem.2024.1458038","article-title":"Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes","volume":"3","author":"Stevenson","year":"2024","journal-title":"Front Dement"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01040_bib29","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1074\/jbc.R112.444158","article-title":"Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling","volume":"288","author":"Fu","year":"2013","journal-title":"J Biol Chem"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2026.e01040_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J Cell Sci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ceb.2007.02.008","article-title":"The EGF receptor family: spearheading a merger of signaling and therapeutics","volume":"19","author":"Bublil","year":"2007","journal-title":"Curr Opin Cell Biol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01040_bib32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210712120","article-title":"Integrated regulation of dopaminergic and epigenetic effectors of neuroprotection in Parkinson\u2019s disease models","volume":"120","author":"Nourse","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01040_bib33","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1172\/JCI85456","article-title":"Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01040_bib34","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1073\/pnas.1712648115","article-title":"Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice","volume":"115","author":"Xiong","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/mds.28389","article-title":"Long-term safety and clinical effects of nilotinib in Parkinson\u2019s disease","volume":"36","author":"Pagan","year":"2021","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib36","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3390\/jcm14124245","article-title":"Safety, cognitive, and behavioral outcomes in patients with dementia with lewy bodies treated with nilotinib","volume":"14","author":"Pagan","year":"2025","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124245","article-title":"Safety, cognitive, and behavioral outcomes in patients with dementia with lewy bodies treated with nilotinib","volume":"14","author":"Pagan","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib37","article-title":"Safety, target engagement, and biomarker effects of bosutinib in dementia with lewy bodies","volume":"8","author":"Pagan","year":"2022","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib38","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1212\/CPJ.0000000000000918","article-title":"Treatment of dementia with bosutinib: an open-label study of a tyrosine kinase inhibitor","volume":"11","author":"Mahdavi","year":"2021","journal-title":"Neurol, Clin Pract"},{"key":"10.1016\/j.neurot.2026.e01040_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41531-026-01275-1","article-title":"Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson\u2019s disease: a phase 2, randomized, double-lind, placebo-controlled study","volume":"12","author":"Sarva","year":"2026","journal-title":"npj Parkinson\u2019s Dis"},{"key":"10.1016\/j.neurot.2026.e01040_bib40","doi-asserted-by":"crossref","first-page":"108020","DOI":"10.1016\/j.parkreldis.2025.108020","article-title":"Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with lewy bodies","volume":"140","author":"Pagan","year":"2025","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.neurot.2026.e01040_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.annepidem.2023.04.019","article-title":"A predictive algorithm to identify ever smoking in medical claims-based epidemiologic studies","volume":"85","author":"Faust","year":"2023","journal-title":"Ann Epidemiol"},{"issue":"24","key":"10.1016\/j.neurot.2026.e01040_bib42","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005678","article-title":"Use of medical care biases associations between Parkinson disease and other medical conditions","volume":"90","author":"Gross","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020430","article-title":"Analysis of epidermal growth factor receptor related gene expression changes in a cellular and animal model of Parkinson's disease","volume":"18","author":"Kim","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e01040_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nbd.2016.06.002","article-title":"Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson\u2019s disease","volume":"94","author":"Padel","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"Pt 8","key":"10.1016\/j.neurot.2026.e01040_bib47","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1093\/brain\/awr165","article-title":"Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia","volume":"134","author":"Ohlin","year":"2011","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01040_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/glia.24109","article-title":"Astrocytic VEGFA: an essential mediator in blood-brain-barrier disruption in Parkinson\u2019s disease","volume":"70","author":"Lan","year":"2022","journal-title":"Glia"},{"issue":"21","key":"10.1016\/j.neurot.2026.e01040_bib49","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/WNL.0000000000002151","article-title":"Increased CSF biomarkers of angiogenesis in Parkinson disease","volume":"85","author":"Janelidze","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01040_bib50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01.wnr.0000215769.71657.65","article-title":"Expression levels of vascular endothelial growth factor and its receptors in Parkinson\u2019s disease","volume":"17","author":"Wada","year":"2006","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/exnr.1998.6933","article-title":"[125I]EGF binding in basal ganglia of patients with Parkinson\u2019s disease and progressive supranuclear palsy and in MPTP-treated monkeys","volume":"154","author":"Villares","year":"1998","journal-title":"Exp Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/01616412.2016.1249997","article-title":"Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson's disease","volume":"38","author":"Pal","year":"2016","journal-title":"Neurol Res"},{"key":"10.1016\/j.neurot.2026.e01040_bib53","doi-asserted-by":"crossref","first-page":"105694","DOI":"10.1016\/j.ebiom.2025.105694","article-title":"Dissection of blood-brain barrier dysfunction through CSF PDGFRbeta and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disorders","volume":"115","author":"Vrillon","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurot.2026.e01040_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mam.2018.01.006","article-title":"PDGF\/PDGFR axis in the neural systems","volume":"62","author":"Sil","year":"2018","journal-title":"Mol Aspect Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01040_bib55","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1471-4159.2007.04567.x","article-title":"Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons","volume":"101","author":"Rite","year":"2007","journal-title":"J Neurochem"},{"issue":"48","key":"10.1016\/j.neurot.2026.e01040_bib56","doi-asserted-by":"crossref","first-page":"41230","DOI":"10.1074\/jbc.M111.270470","article-title":"Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein","volume":"286","author":"Lee","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1523\/JNEUROSCI.4493-06.2007","article-title":"Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion","volume":"27","author":"Timmer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2026.e01040_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.148893","article-title":"Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: modulation of dopamine D3 receptor","volume":"1834","author":"Mansour","year":"2024","journal-title":"Brain Res"},{"issue":"13","key":"10.1016\/j.neurot.2026.e01040_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131799","article-title":"LRRK2 kinase inhibition attenuates neuroinflammation and cytotoxicity in animal models of alzheimer\u2019s and Parkinson\u2019s disease-related neuroinflammation","volume":"12","author":"Mutti","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neurot.2026.e01040_bib60","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.nbd.2023.105997","article-title":"Cross-sectional proteomic expression in Parkinson\u2019s disease-related proteins in drug-naive patients vs healthy controls with longitudinal clinical follow-up","volume":"177","author":"Abdi","year":"2023","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/glia.22767","article-title":"c-Src function is necessary and sufficient for triggering microglial cell activation","volume":"63","author":"Socodato","year":"2015","journal-title":"Glia"},{"issue":"48","key":"10.1016\/j.neurot.2026.e01040_bib63","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1038\/sj.onc.1208162","article-title":"Not so strange bedfellows: G-protein-coupled receptors and Src family kinases","volume":"23","author":"Luttrell","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01040_bib64","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0028-3908(01)00121-6","article-title":"Constitutive tyrosine phosphorylation of the GABA(A) receptor gamma 2 subunit in rat brain","volume":"41","author":"Brandon","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1074\/jbc.M008085200","article-title":"Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor","volume":"276","author":"Nakazawa","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2026.e01040_bib66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2020.00033","article-title":"Molecular signatures of neuroinflammation induced by alphaSynuclein aggregates in microglial cells","volume":"11","author":"Sarkar","year":"2020","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.neurot.2026.e01040_bib67","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1523\/JNEUROSCI.4658-15.2016","article-title":"Inhibition of the JAK\/STAT pathway protects against alpha-synuclein-induced neuroinflammation and dopaminergic neurodegeneration","volume":"36","author":"Qin","year":"2016","journal-title":"J Neurosci"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01040_bib68","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1212\/NXG.0000000000000633","article-title":"CSF MicroRNAs reveal impairment of angiogenesis and autophagy in parkinson disease","volume":"7","author":"Fowler","year":"2021","journal-title":"Neurol Genet"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01040_bib69","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib70","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12974-023-02802-0","article-title":"Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer\u2019s disease","volume":"20","author":"Stevenson","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"17","key":"10.1016\/j.neurot.2026.e01040_bib71","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/hmg\/ddaa177","article-title":"Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases","volume":"29","author":"Fowler","year":"2020","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s Disease","volume":"88","author":"Turner","year":"2020","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01040_bib73","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3390\/jcm14124245","article-title":"Safety, cognitive, and behavioral outcomes in patients with dementia with lewy bodies treated with nilotinib","volume":"14","author":"Pagan","year":"2025","journal-title":"J Clin Med"},{"issue":"10314","key":"10.1016\/j.neurot.2026.e01040_bib74","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01040_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children's Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.neurot.2026.e01040_bib76","article-title":"Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01040_bib77","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metabol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib78","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01040_bib79","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-20-0683","article-title":"Therapy of endocrine disease: endocrine-Metabolic effects of treatment with multikinase inhibitors","volume":"184","author":"Fallahi","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01040_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251852","article-title":"Parkinson's disease case ascertainment in a large prospective cohort","volume":"16","author":"Shrestha","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e01040_bib81","article-title":"Validation of a parkinson disease predictive model in a population-based study","volume":"2020","author":"Faust","year":"2020","journal-title":"Parkinsons Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:07:38Z","timestamp":1790125658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926002102"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01040","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01040"}}